Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 3/20 | 0.68 |
| ▸ | TUBB | P07437 | 3/20 | 0.68 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.68 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.68 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.68 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.68 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.68 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.68 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.68 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.68 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.68 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.68 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.68 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.68 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.68 |
| ▸ | MYB | P10242 | 15/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4540411 | 0.91 | TUBB4A (0.72) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4539561 | 0.90 | TUBB4A (0.62) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4537606 | 0.90 | TUBB4A (0.71) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4541136 | 0.88 | TUBB4A (0.69) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4541490 | 0.86 | TUBB4A (0.67) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4331540 | 0.86 | MYB (0.87) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4537843 | 0.86 | TUBB4A (0.68) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL19732221 | 0.84 | TUBB4A (0.70) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4539906 | 0.83 | TUBB4A (0.65) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL4319288 | 0.83 | TUBB4A (0.67) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2638025-B1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM DKFZ (DE) | 2020-02-05 | — | — | EP | disclosed |
| EP-2638025-B1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM DKFZ (DE) | 2020-02-05 | — | — | EP | disclosed |
| US-20180334442-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS | Ruprecht-Karls-Universität Heidelberg (DE) | 2018-11-22 | — | — | US | disclosed |
| US-10065939-B2 | Chromene derivatives and their analogs as Wnt pathway antagonists | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2018-09-04 | — | — | US | disclosed |
| EP-2638026-B1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM DKFZ (DE) | 2018-07-11 | — | — | EP | disclosed |
| EP-2638026-B1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM DKFZ (DE) | 2018-07-11 | — | — | EP | disclosed |
| US-20160355496-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2016-12-08 | — | — | US | disclosed |
| US-20160355496-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2016-12-08 | — | — | US | disclosed |
| US-20160355496-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2016-12-08 | — | — | US | disclosed |
| US-9371333-B2 | Chromene derivatives and their analoga as Wnt pathway antagonists | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2016-06-21 | — | — | US | disclosed |
| US-20130303550-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG (DE) | 2013-11-14 | — | — | US | disclosed |
| US-20130296344-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG (DE) | 2013-11-07 | — | — | US | disclosed |
| US-20130296344-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG (DE) | 2013-11-07 | — | — | US | disclosed |
| US-20130296344-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG (DE) | 2013-11-07 | — | — | US | disclosed |
| EP-2638026-A2 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | Deutsches Krebsforschungszentrum (DKFZ) (DE) | 2013-09-18 | — | — | EP | disclosed |
| EP-2638025-A2 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | Deutsches Krebsforschungszentrum (DKFZ) (DE) | 2013-09-18 | — | — | EP | disclosed |
| WO-2012062901-A2 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DKFZ) (DE) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012062905-A2 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DKFZ) (DE) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012062901-A2 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DKFZ) (DE) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012062905-A2 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DKFZ) (DE) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303550-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | WNT3, WNT1, WNT3A | TUBB4A 2905/4885TUBB 3789/4885TUBA3C 2948/4885 |
| US-20160355496-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS | WNT3, WNT1, WNT3A | TUBB4A 3213/4885TUBB 3786/4885TUBA3C 3064/4885 |
| US-10065939-B2 | Chromene derivatives and their analogs as Wnt pathway antagonists | WNT3, WNT1, WNT3A | TUBB4A 3213/4885TUBB 3786/4885TUBA3C 3064/4885 |
| US-20130296344-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGA AS WNT PATHWAY ANTAGONISTS | WNT3, WNT1, WNT3A | TUBB4A 3809/4885TUBB 4669/4885TUBA3C 4637/4885 |
| US-20180334442-A1 | CHROMENE DERIVATIVES AND THEIR ANALOGS AS WNT PATHWAY ANTAGONISTS | WNT3, WNT1, WNT3A | TUBB4A 3213/4885TUBB 3786/4885TUBA3C 3064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.